Epidermal growth factor receptor inhibitors in colorectal cancer treatment:: What's new?
Epidermal growth factor receptor inhibitors in colorectal cancer treatment:: What's new?
复制标题
DOI：
10.3748/wjg.v13.i44.5877
复制
发表时间：
2007-11-28
影响因子：
4.3
通讯作者：
Gil-Bazo, I.
中科院分区：
文献类型：
--
作者：
Ponz-Sarvise, M.;Rodriguez, J.;Gil-Bazo, I.
结直肠癌是西方世界最常见的恶性肿瘤之一，也是癌症死亡的第二大原因，全世界每年有100万新发病例和50万例死亡。转移性结肠癌患者的治疗包括不同的化疗化合物方案（氟嘧啶、伊立替康和奥沙利铂）和新的靶向治疗。有趣的是，最近尝试将患者暴露于所有五种药物类别（氟嘧啶，伊立替康，奥沙利铂，贝伐单抗和西妥昔单抗）的试验实现了超过2年的总生存期。在这篇综述中，我们将重点介绍主要的表皮生长因子受体抑制剂，主要是西妥昔单抗，帕尼单抗，厄洛替尼和吉非替尼证明结直肠癌的临床效益。我们还将简要描述其背后的分子步骤，以及报告的耐药和反应的不同临床或分子机制。(C)2007年WJG。All rights reserved.
Colorectal cancer constitutes one of the most common malignancies and the second leading cause of death from cancer in the western world representing one million new cases and half a million deaths annually worldwide. The treatment of patients with metastatic colon cancer comprises different regimens of chemotherapeutic compounds (fluoropyrimidines, irinotecan and oxaliplatin) and new targeted therapies. Interestingly, most recent trials that attempt to expose patients to all five-drug classes (fluoropyrimidines, irinotecan, oxaliplatin, bevacizumab and cetuximab) achieve an overall survival well over 2 years. In this review we will focus on the main epidermal growth factor receptor inhibitors demonstrating clinical benefit for colorectal cancer mainly cetuximab, panitumumab, erlotinib and gefitinib. We will also describe briefly the molecular steps that lie beneath them and the different clinical or molecular mechanisms that are reported for resistance and response. (C) 2007 WJG. All rights reserved.